Background and Aims: The Bezold-Jarisch reflex (BJR) is considered to contribute to subarachnoid block (SAB)-induced hypotension and bradycardia and is mediated by serotonin receptors (5-HT 3 subtype). Ondansetron, a 5-HT 3 receptor antagonist, is assumed to block the effect of serotonin and inhibit BJR. The aim was to study the effect of intravenous ondansetron on maternal hemodynamics. Materials and Methods: The study was conducted on 150 healthy parturients scheduled for elective caesarean section under SAB who were randomly allocated into two groups of 75 each to receive either 4 mg ondansetron or 0.9% normal saline 10 min before initiation of SAB. Hemodynamic parameters were studied from the time of administration of the study drug upto the time of delivery of baby. Results: Both the groups were comparable to each other with respect to baseline hemodynamic parameters. SAB-induced fall in systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) was significantly less in the ondansetron group when compared with placebo from the time of initiation of SAB upto 12 min of surgery time (P < 0.05). However, the difference in heart rate between both groups was not statistically significant. The total use of vasopressors was significantly low in ondansetron group when compared with placebo (P < 0.05). Better neonatal outcomes were observed in the ondansetron group. Conclusion: Intravenous ondansetron premedication can successfully attenuate SAB-induced fall in SBP, DBP, and MAP in parturients undergoing elective caesarean sections.
Introduction
Subarachnoid block (SAB) is the most commonly used anesthetic technique for elective caesarean sections, [1] with associated complications including hypotension and bradycardia with a reported incidence of 33% and 13%, respectively, for nonobstetric population and upto 50%-60% in obstetric population. [2] Caesarean sections require a sensory block till T4 level which leads to an extended sympathetic block involving the entire thoracolumbar outflow. [3] This leads to decrease in preload by venodilation and decrease in afterload by causing a decrease in systemic vascular resistance thus causing a fall in the mean arterial pressure (MAP). [4] This fall in MAP is exaggerated by the physiological changes in pregnancy along with compression of the vena cava by the gravid uterus. [5] The Bezold-Jarisch Reflex (BJR), a cardioinhibitory reflex mediated by This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com serotonin receptors (5-HT 3 ) present on the vagus nerve and within the walls of cardiac ventricles, is also known to contribute to hypotension and bradycardia induced by SAB. [6] Activation of these receptors occurs due to a sudden decrease in left ventricular volume which may be seen with hypovolemia, orthostasis, regional anesthesia, and aortocaval compression during pregnancy. [6] This leads to sudden activation of the parasympathetic system and sympathetic withdrawal causing vasodilation, bradycardia, and hypotension. [7] Ondansetron, a widely used antiemetic, [8] is a 5-HT 3 antagonist that is assumed to block the effect of serotonin which can directly trigger the BJR. We hypothesize to use ondansetron prophylactically to attenuate hypotension and bradycardia after SAB in both nonobstetric and obstetric patients, thereby limiting the need for vasopressors and other modalities to maintain hemodynamic stability. [9] [10] [11] Submission : 18-June-2019 Revision : 20-June-2019 Accepted : 09-July-2019
Materials and Methods
The study was conducted after approval from the Institutional ethics committee (January 2016) in a randomized double-blind method on a total of 150 parturients scheduled for elective lower segment caesarean section under SAB. A written informed consent was taken from all the patients before the procedure.
Parturients were allocated randomly into two groups: group O -parturients received 4 mg (2 mL) ondansetron diluted to 10 mL of 0.9% normal saline 10 min before administration of SAB and group P -parturients received 10 mL of 0.9% normal saline 10 min before administration of SAB.
Parturients undergoing elective lower segment caesarean section under SAB with American Society of Anesthesiologists (ASA) grade II were included in the study. Exclusion criteria included uncooperative and unwilling parturients, history of uncontrolled hypertension, gestational hypertension, pre-eclampsia, eclampsia, uncontrolled diabetes mellitus, cardiac disease, parturients with prolonged QT interval on electrocardiogram (ECG), known drug allergy to ondansetron, contraindications to neuraxial anesthesia, failed SAB, and its conversion to general anesthesia or planned general anesthesia.
The study drug was administered 10 min prior to administration of SAB. Monitoring in the form of heart rate (HR), noninvasive blood pressure, respiratory rate (RR), peripheral oxygen saturation (SpO 2 ), and ECG was done by a blinded observer. SAB was performed with 2.2 mL bupivacaine 0.5% (hyperbaric) using 26-gauge Quincke's needle. Any significant change in hemodynamics in the post SAB period was noted. Hypotension was defined as systolic blood pressure (SBP) less than 20% of the baseline. This was considered as the threshold for treatment of hypotension. The treatment was standardized to an infusion of balanced salt solution and injection phenylephrine in boluses of 20 µg intravenously (i.v.). Any episode of intraoperative bradycardia with HR less than 50 beats/min was managed with injection atropine 0.01 mg/kg i.v. After the delivery of the baby, uterotonic drug in the form of injection oxytocin was administered as an i.v. bolus of 5 units followed by an infusion of 20 units in 500 mL normal saline over a period of 30 min. This period after the delivery of baby was excluded from the study to remove any confounding effect of uterotonic drugs on blood pressure readings.
Outcome measures
The primary outcome included BP and HR in the two groups from the time of initiation of SAB upto the time of delivery.
The secondary outcomes consisted of the total amount of fluid administered, amount of phenylephrine and atropine used, and Apgar score at 1 and 5 min.
Statistical analysis
Data were described in terms of range, mean ± standard deviation, median, frequencies (number of cases), and relative frequencies (percentages) as appropriate.
Comparison of quantitative variables between the study groups was done using Student's t-test and Mann-Whitney U-test for independent samples for parametric and nonparametric data, respectively. For comparing categorical data, Chi-square (χ 2 ) test was performed and exact test was used when the expected frequency is less than 5. A probability value (P value) less than 0.05 was considered statistically significant. All statistical calculations were done using Statistical Package for the Social Science (SPSS) version 21 statistical program for Microsoft Windows.
Results
A total of 150 parturients were included in our study. None of the parturients were excluded and both the groups were statistically comparable with respect to age, weight, and ASA grade. The baseline HR, SBP, diastolic blood pressure (DBP), and MAP were comparable between both the groups [ Table 1 ].
On intergroup comparison from the time of administration of study drug to the time of delivery of the baby, the difference in mean HR was statistically insignificant with P > 0.05 at all times during the study period [ Figure 1 ]. Higher mean SBP recordings were observed in group O when compared with group P immediately after the administration of SAB (P < 0.05), incision time (P < 0.05), 2 min (P < 0.05), 4 min (P < 0.05), 6 min (P < 0.05), 8 min (P < 0.05), 10 min (P < 0.05), and 12 min (P < 0.05) and the difference between both the groups was statistically significant. The difference in mean SBP was insignificant at other times during the study period [ Figure 2 ]. Higher mean DBP recordings were observed in group O at the time of administration of SAB (P < 0.05), incision time (P < 0.05), 2 min (P < 0.05), 4 min (P < 0.05), 6 min (P < 0.05), 8 min (P < 0.05), 10 min (P < 0.05), and 12 min (P < 0.05) and this difference between both the groups was statistically significant. The difference in mean DBP was insignificant at other times during the study period [ Figure 3 ]. Observed MAP recordings were higher in group O at the time of administration of SAB (P < 0.05), incision time (P < 0.05), 2 min (P < 0.05), 4 min (P < 0.05), 6 min (P < 0.05), 8 min (P < 0.05), 10 min (P < 0.05), and 12 min (P < 0.05) and the difference between both the groups was statistically significant. The difference in MAP was insignificant at other times during the study period [ Figure 4 ]. The mean oxygen saturation, RR, total intraoperative blood loss, and total use of atropine were comparable between both the groups. The total intraoperative fluid requirement was lower in group O when compared with group P and the difference was statistically significant with P < 0.05 [ Figure 5 ]. The mean total use of phenylephrine was lower in group O when compared with group P and the difference between both the groups was statistically significant with P < 0.05 [ Figure 6 ]. Neonatal parameters were also better with the use of ondansetron as observed by statistically significant difference in Apgar score at 1 min (P < 0.05).
Discussion
SAB for caesarean sections is associated with significant bradycardia and hypotension which may compromise the health of the mother and the fetus. It produces vasodilation, hypotension, and bradycardia by sympathetic blockade and BJR via stimulation of 5-HT 3 receptors in vagal nerve endings. [10] However, in some cases tachycardia may occur: (1) as a compensatory response to a rapid reduction in systemic vascular resistance, [12] (2) due to severe local anesthetic systemic toxicity, [13] and (3) associated with ST segment changes. [14] In this study, it was postulated that ondansetron can prevent SAB-induced bradycardia and hypotension by preventing serotonin-induced BJR. Ondansetron is a highly selective 5-HT3 receptor antagonist, has onset of action in less than 30 min (i.v. administration), peak effect in 10 min, half-life of approximately 4 h, and exact duration unknown. The dose of ondansetron used in our study was 4 mg. It was found to be the optimal dosage for prevention of maternal hypotension during caesarean sections in a previous study conducted by Wang et al. [8] and also because of increased risk of QT prolongation with higher doses. We observed that in group O, where parturients received 4 mg ondansetron 10 min before initiation of SAB, the fall in SBP, DBP, and MAP was significantly less when compared with the placebo group. This attenuation was observed from the time of initiation of SAB upto 12 min of surgery time. However, we did not observe any effect of ondansetron on HR at any time during the study period, contrary to their findings. [15] This difference may be attributed to an infrequent incidence of bradycardia in both the groups. With respect to HR, our results were consistent with the findings of Owczuk R, et al., Sahoo, et [9, 10, [15] [16] [17] Sahoo et al. and Wang et al. observed attenuation of fall in SBP and MAP with the use of ondansetron in caesarean sections. However, none of these studies reported a statistically significant effect of ondansetron on DBP which was observed in our study. This can be ascribed to a small sample size in their studies (n = 52 and 66, respectively) which could not achieve statistical significance when compared with 150 parturients in our study. [10, 16] Our results are contrary to the findings of Ortiz-Gomez et al., Marciniak et al., and Terkawi et al. who found ondansetron to be ineffective in attenuating both hypotension and bradycardia after administration of SAB. [6, 18, 19] This could be due to difference in the dose of bupivacaine used or due to addition to opioid adjuncts intrathecally in their studies.
With respect to the mean total use of vasopressor (phenylephrine), our results are consistent with the findings of Marashi et al., Sahoo et al., and Wang et al. in terms of decreased vasopressor requirement with the use of ondansetron when compared with a placebo. [10, 16, 17] A statistical significance difference in the total amount of fluid administered was observed (P < 0.05) which may be attributed to higher amounts of vasopressor and fluid requirements of the placebo group to maintain SBP within 80% of the baseline value. None of the previous studies has commented upon the effect of ondansetron on the total intraoperative fluid requirement of the parturient. Only two patients in the placebo group required the use of atropine for the management of bradycardia after administration of SAB when compared with none in the ondansetron group and the difference was not statistically significant (P = 0.157). With respect to the neonatal parameters, the difference in mean Apgar score at 1 min between the two groups was statistically significant (P = 0.013).
The study period was specifically restricted between subarachnoid administration of local anesthetic and the delivery of baby to avoid confounding by the effects of uterotonic drugs, blood loss during the extraction of placenta, and vagal responses to uterine externalization.
The limitations of our study include inability to evaluate the effect of ondansetron on the total duration of sensory and motor blockade. In addition, we also cannot comment upon its effect on HR due to an infrequent occurrence of bradycardia in our study population. Our study was superior to the other studies in terms of a large sample size including 150 parturients. Also, ondansetron was administered 10 min before the initiation of SAB to achieve its peak action when compared with 5 minutes in previous studies.
Conclusion
We conclude that i.v. ondansetron premedication can successfully attenuate SAB-induced fall in SBP, DBP, and MAP in parturients scheduled for elective caesarean sections.
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